Ekso Bionics Holdings, Inc. Stock

$3.38

2.03% day before yesterday

Nasdaq, Jul 11, 10:00 pm CET

ISIN

US2826442020

Symbol

EKSO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Ekso Bionics Holdings, Inc. Stock price

$3.38

-118.57 97.23% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-0.07 2.03%

ISIN

US2826442020

Symbol

EKSO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$8.1m

Enterprise Value

$4.9m

Net debt

positive

Cash

$8.1m

Shares outstanding

1.9m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

0.5 | 0.5

EV/Sales

0.3 | 0.3

EV/FCF

negative

P/B

0.6

Financial Health

Equity Ratio

47.7%

Return on Equity

-89.2%

ROCE

-55.8%

ROIC

Debt/Equity

0.4

Financials (TTM | estimate)

Revenue

$17.5m | $18.0m

EBITDA

$-8.9m | -

EBIT

$-10.5m | $-10.7m

Net Income

$-10.8m | $-10.4m

Free Cash Flow

$-8.4m

Growth (TTM | estimate)

Revenue

-2.1% | 0.2%

EBITDA

27.3% | -

EBIT

24.8% | -2.4%

Net Income

24.2% | 8.6%

Free Cash Flow

26.8%

EPS

$-6.4

FCF per Share

$-4.5

Short interest

1.2%

Employees

Rev per Employee

$280.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Ekso Bionics Holdings, Inc. Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Ekso Bionics Holdings, Inc. forecast:

7x Buy

88%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Ekso Bionics Holdings, Inc. forecast:

Buy

88%

Hold

13%

Analyst Estimates with Stock Price Targets

Financial data from Ekso Bionics Holdings, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	18 18	2% 2% 100%
- Direct Costs	8.18 8.18	8% 8% 47%
Gross Profit	9.37 9.37	4% 4% 53%
- Selling and Administrative Expenses	16 16	10% 10% 92%
- Research and Development Expense	3.73 3.73	26% 26% 21%
EBITDA	-8.88 -8.88	27% 27% -51%
- Depreciation and Amortization	1.58 1.58	7% 7% 9%
EBIT (Operating Income) EBIT	-10 -10	25% 25% -60%
Net Profit	-11 -11	24% 24% -62%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Ekso Bionics Holdings, Inc. Stock News

Neutral

GlobeNewsWire

●

25 days ago

Ekso Bionics' Acceptance into NVIDIA Connect Program Bears Early Fruit

AI voice agent for user interface being designed to support exoskeleton device operation, motivation, training, and safety First proof-of-concept demonstration comes just over a month after Company announced its acceptance into the NVIDIA Connect Program SAN RAFAEL, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industr...

Neutral

GlobeNewsWire

●

about 2 months ago

Ekso Bionics Announces New Effective Date of Reverse Stock Split

SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it has updated the effective date of its reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m., Pacific time, rather than the previously disclosed...

Neutral

GlobeNewsWire

●

about 2 months ago

Ekso Bionics Announces Reverse Stock Split

SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27, 2025 at 12:01 a.m. Pacific time. The Company's common stock will open for tradin...

More Ekso Bionics Holdings, Inc. News

Company Profile

Ekso Bionics Holdings, Inc. engages in the design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following business segments: EksoHealth, EksoWorks, and Other. The EksoHealth segment consists of the engineering, manufacture, and sale of exoskeletons for applications in the medical markets. The EksoWorks segment offers exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. The company was founded on January 30, 2012 and is headquartered in Richmond, CA.

Head office	United States
CEO	Scott Davis
Employees	64
Founded	2012
Website	eksobionics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now